Home PharmEasy plans to procure $300 million at reduced valuation; potential first major Indian down round

PharmEasy plans to procure $300 million at reduced valuation; potential first major Indian down round

PharmEasy plans to raise $300 million in funding at a 90% markdown, reducing its valuation by half.
Healthcare group Manipal might lead this round; the start-up aims to repay its loan from Goldman Sachs.
If successful, this new round will bring PharmEasy’s valuation down to $500 million-$600 million, marking the first major down round for an Indian unicorn.